Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5245 | 195962-23-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as (rec)FSH, but with a markedly prolonged duration of FSH activity. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of Corifollitropin alfa may replace the first seven injections of any daily (rec)FSH preparation in a COS treatment cycle. The long duration of FSH activity was achieved by adding the carboxy-terminal peptide of the beta-subunit of human chorionic gonadotropin (hCG) to the beta-chain of human FSH. Corifollitropin alfa does not display any intrinsic LH/hCG activity.
|
| Dose | Unit | Route |
|---|---|---|
| 0.15 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 25, 2010 | EMA | Merck Sharp & Dohme Limited |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 141.80 | 130.13 | 20 | 85 | 5842 | 90622500 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | 147.57 | 119.25 | 20 | 85 | 5340 | 110583854 |
None
| Source | Code | Description |
|---|---|---|
| ATC | G03GA09 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM GONADOTROPINS AND OTHER OVULATION STIMULANTS Gonadotropins |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Adolescent males with hypogonadotropic hypogonadism | indication | 33927004 | |
| Ovulation induction | indication | 61285001 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Follicle-stimulating hormone receptor | GPCR | AGONIST | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
| ID | Source |
|---|---|
| T7K20Y2GWY | UNII |
| C2713522 | UMLSCUI |
| CHEBI:753193 | CHEBI |
| CHEMBL2108185 | ChEMBL_ID |
| DB09066 | DRUGBANK_ID |
| D08895 | KEGG_DRUG |
| 7738 | INN_ID |
| C437186 | MESH_SUPPLEMENTAL_RECORD_UI |
| 703830001 | SNOMEDCT_US |
| 715488000 | SNOMEDCT_US |
| 013500 | NDDF |
None